High-Volume Scanners

WHITE PAPERS AND CASE STUDIES

• Benefits Of Implementing EDC & Medical Coding With RTSM

  Discover what happened when the Fountayn Platform, including RTSM, was used to support a client’s two-year, Phase III study seeking a cure for multiple sclerosis.

• CDMO Supports Complex Bispecific Antibody Development

  Read how the expertise, resources and flexibility of one partner have been fundamental in advancing novel and complex bispecific antibody candidates that target the WNT pathway.

• Cottage Grove Municipal Treatment System Removes PFAS Compounds From Well Water Using Granular Activated Carbon

  Located in the Twin Cities metro area, the city of Cottage Grove, Minnesota, needed to increase the capacity of its drinking water system. To meet demands for compliant water two additional wells were equipped with treatment systems designed to reduce PFAS. The city contracted consulting firm Stantec to provide engineering services for the design, during procurement, construction of the facilities and site infrastructure for the dual media granulated activated carbon (GAC) and/or Ion Exchange (IX) equipment systems.

• Auto-Injector Assembly: Flexible And Scalable Production Is Key

  A range device assembly machine with the ability to implement several auto-injector formats, and allow rapid, tool-free changeover time of less than two hours provides a solution for PCI Pharma Services.

• Vision And Paperless Ops Make Northeast Scientific A MedTech Industry Leader

  Managing all the documentation for the many devices Northeast Scientific remanufactured was complex and prone to errors. A modern manufacturing execution system allowed them to manage documentation by eliminating paper.

• Effects Of Mobility On mmWave Beamforming In Dynamic, Urban Environments

  Learn how massive MIMO beamforming mitigates mmWave propagation challenges using Wireless InSite and its mmWave hybrid beamformer.

• An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market

  Biotech and biopharma developers are increasingly relying on outsourcing partners to meet both clinical and commercial research, development, and production needs. CDMOs that provide end-to-end services, including secure supply chains, can help biologics developers meet accelerated timelines and establish a real competitive advantage in today’s competitive market.

• Why It’s Critical For Businesses To Implement A Cyber Resilience Framework

  Cyber resilience, the ability to maintain business operations in the face of unending and evolving cyber threats, can be an intimidating topic for any business. Adding to the challenge is the complexity of companies’ IT footprints — which today are often a distributed web of cloud applications, private servers, and employee devices. Critical data, the currency of business, is spread across this footprint and stored in documents, spreadsheets, electronic communications, and databases. This data powers business. When access to data is disrupted, as with a ransomware attack, the implications can be crippling.

• Tips For Tailoring eConsent For Optimal Patient Centricity

  While informed consent is a critical process for ensuring participant autonomy, consent forms are too long, unclear, difficult to read, and frequently exceed 9th grade reading levels. Explore why eConsent is a potential solution to this problem.

• Precision Powder-In-Capsule Micro-Dosing Accelerates Drug Development

  Precision powder microdosing makes it possible to quickly get formulations to the clinic, saving time, money, and use of limited APIs.

• Camuzzi Gas: Planning And Mobilization Of Field Service Activities

  Camuzzi Gas Pampeana S.A. and Camuzzi Gas del Sur S.A. form the largest supplier of natural gas in Argentina, covering around 45% of the country, i.e. a 3,100 km wide area. The companies serve 2.5 million clients and manage 10,000 km of gas pipelines as well as a 50.000 km long gas supply network.

• Challenges And Solutions In Cell And Gene Therapy Manufacturing

  Discover the three major challenges cell and gene therapy manufacturers are facing today and experienced insights on how to overcome them.